Sedivention
Private Company
Funding information not available
Overview
Sedivention is a Munich-based, privately-held medical device startup pioneering a novel interventional weight-loss therapy. The company's core technology is a cryo-ablation catheter designed to disrupt the gastric vagal nerve trunks in a brief, one-time procedure, aiming to deliver long-term reduction of hunger. Founded in 2021 (with roots from 2016), the company is in the pre-clinical/early development stage, backed by grants and venture capital, and is actively building its network and commercial strategy for future clinical and regulatory milestones.
Technology Platform
Cryo-ablation catheter system designed for minimally invasive, one-time disruption of the gastric vagal nerve trunks to induce long-term reduction of hunger sensation.
Opportunities
Risk Factors
Competitive Landscape
Sedivention competes in the dynamic obesity treatment market against powerful incumbents, including pharmaceutical giants with GLP-1 agonists (e.g., Novo Nordisk, Eli Lilly), providers of bariatric surgery, and other medical device companies with gastric balloons or electrical stimulation systems. Its success hinges on demonstrating superior convenience, durability, and/or safety compared to these established and emerging modalities.